Product Images Duloxetine Hydrochloride Delayed Release

The given text is a graphical representation of the Proportion of Patients with Relapse in a clinical trial comparing the effectiveness of a placebo and Duloxetine treatment. The horizontal axis represents time from randomization to relapse in days, and the vertical axis represents the proportion of patients experiencing relapse. The graph shows that Duloxetine treatment resulted in a lower proportion of patients experiencing relapse compared to the placebo. The outcome can be seen at different time periods post-randomization, with the highest proportion of relapse occurring in the placebo group.*

The text represents a graph showing the proportion of patients with relapse after treatment with a placebo or duloxetine. The horizontal axis represents the time from randomization to relapse in days, while the vertical axis shows the proportion of patients with relapse. The graph shows that patients treated with duloxetine had a lower relapse proportion compared to patients treated with a placebo.*

The text provided shows a chart with the percentage of Patients Improved and Percent Improvement in Pain from Baseline (BOCF). The chart compares the placebo with DUL 60/120 mg taken once daily. The chart indicates that there is a 100% improvement in patients that took DUL 60/120 mg, while there is no improvement in patients that took the placebo.*

This is a description of a medication called Duloxetine Hydrochloride USP, which comes in the form of a delayed-release capsule. Each capsule contains 44.9 mg, which is equivalent to 40 mg of duloxetine. The medication should be stored at around 25°C (77°F), with excursions of 15-30°C (59-86°F) permitted, and should be kept in a tightly closed container. This medication is distributed by Innovida Pharmaceutique Corporation and is made in Spain. The accompanying literature should be referred to for dosage information. BATCH number 182218 has an expiration date of 2020-09.*